Donja M Mijnarends1, Annemarie Koster2, Jos M G A Schols3, Judith M M Meijers4, Ruud J G Halfens4, Vilmundur Gudnason5, Gudny Eiriksdottir6, Kristin Siggeirsdottir6, Sigurdur Sigurdsson6, Pálmi V Jónsson7, Osorio Meirelles8, Tamara Harris8. 1. CAPHRI/Department of Health Services Research, Maastricht University, Maastricht, The Netherlands d.mijnarends@maastrichtuniversity.nl. 2. CAPHRI/Department of Social Medicine, Maastricht University, Maastricht, The Netherlands. 3. CAPHRI/Department of Health Services Research, Maastricht University, Maastricht, The Netherlands CAPHRI/Department of Family Medicine, Maastricht University, Maastricht, The Netherlands. 4. CAPHRI/Department of Health Services Research, Maastricht University, Maastricht, The Netherlands. 5. Faculty of Medicine, University of Iceland, Reykjavik, Iceland Icelandic Heart Association Research Institute, Kopavogur, Iceland. 6. Icelandic Heart Association Research Institute, Kopavogur, Iceland. 7. Faculty of Medicine, University of Iceland, Reykjavik, Iceland Department of Geriatrics, Landspitali National University Hospital, Reykjavik, Iceland. 8. Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Bethesda, MD, USA.
Abstract
BACKGROUND: the prevalence of sarcopenia increases with age. Physical activity might slow the rate of muscle loss and therewith the incidence of sarcopenia. OBJECTIVE: to examine the association of physical activity with incident sarcopenia over a 5-year period. DESIGN: data from the population-based Age, Gene/Environment, Susceptibility-Reykjavik Study were used. SETTING: people residing in the Reykjavik area at the start of the study. SUBJECTS: the study included people aged 66-93 years (n = 2309). METHODS: the amount of moderate-vigorous physical activity (MVPA) was assessed by a self-reported questionnaire. Sarcopenia was identified using the European Working Group on Sarcopenia in Older People algorithm, including muscle mass (computed tomography imaging), grip strength (computerised dynamometer) and gait speed (6 m). RESULTS: mean age of the participants was 74.9 ± 4.7 years. The prevalence of sarcopenia was 7.3% at baseline and 16.8% at follow-up. The incidence proportion of sarcopenia over 5 years was 14.8% in the least-active individuals and 9.0% in the most-active individuals. Compared with the least-active participants, those reporting a moderate-high amount of MVPA had a significantly lower likelihood of incident sarcopenia (OR = 0.64, 95% CI 0.45-0.91). Participants with a high amount of MVPA had higher baseline levels of muscle mass, strength and walking speed, but baseline MVPA was not associated with the rate of muscle loss. CONCLUSION: a higher amount of MVPA seems to contribute to counteracting the development of sarcopenia. To delay the onset of sarcopenia and its potential adverse outcomes, attention should be paid to increasing physical activity levels in older adults.
BACKGROUND: the prevalence of sarcopenia increases with age. Physical activity might slow the rate of muscle loss and therewith the incidence of sarcopenia. OBJECTIVE: to examine the association of physical activity with incident sarcopenia over a 5-year period. DESIGN: data from the population-based Age, Gene/Environment, Susceptibility-Reykjavik Study were used. SETTING:people residing in the Reykjavik area at the start of the study. SUBJECTS: the study included people aged 66-93 years (n = 2309). METHODS: the amount of moderate-vigorous physical activity (MVPA) was assessed by a self-reported questionnaire. Sarcopenia was identified using the European Working Group on Sarcopenia in Older People algorithm, including muscle mass (computed tomography imaging), grip strength (computerised dynamometer) and gait speed (6 m). RESULTS: mean age of the participants was 74.9 ± 4.7 years. The prevalence of sarcopenia was 7.3% at baseline and 16.8% at follow-up. The incidence proportion of sarcopenia over 5 years was 14.8% in the least-active individuals and 9.0% in the most-active individuals. Compared with the least-active participants, those reporting a moderate-high amount of MVPA had a significantly lower likelihood of incident sarcopenia (OR = 0.64, 95% CI 0.45-0.91). Participants with a high amount of MVPA had higher baseline levels of muscle mass, strength and walking speed, but baseline MVPA was not associated with the rate of muscle loss. CONCLUSION: a higher amount of MVPA seems to contribute to counteracting the development of sarcopenia. To delay the onset of sarcopenia and its potential adverse outcomes, attention should be paid to increasing physical activity levels in older adults.
Authors: René Rizzoli; Jean-Yves Reginster; Jean-François Arnal; Ivan Bautmans; Charlotte Beaudart; Heike Bischoff-Ferrari; Emmanuel Biver; Steven Boonen; Maria-Luisa Brandi; Arkadi Chines; Cyrus Cooper; Sol Epstein; Roger A Fielding; Bret Goodpaster; John A Kanis; Jean-Marc Kaufman; Andrea Laslop; Vincenzo Malafarina; Leocadio Rodriguez Mañas; Bruce H Mitlak; Richard O Oreffo; Jean Petermans; Kieran Reid; Yves Rolland; Avan Aihie Sayer; Yannis Tsouderos; Marjolein Visser; Olivier Bruyère Journal: Calcif Tissue Int Date: 2013-07-05 Impact factor: 4.333
Authors: Wojtek J Chodzko-Zajko; David N Proctor; Maria A Fiatarone Singh; Christopher T Minson; Claudio R Nigg; George J Salem; James S Skinner Journal: Med Sci Sports Exerc Date: 2009-07 Impact factor: 5.411
Authors: C K Liu; X Leng; F-C Hsu; S B Kritchevsky; J Ding; C P Earnest; L Ferrucci; B H Goodpaster; J M Guralnik; L Lenchik; M Pahor; R A Fielding Journal: J Nutr Health Aging Date: 2014-01 Impact factor: 4.075
Authors: Pedro C Hallal; Lars Bo Andersen; Fiona C Bull; Regina Guthold; William Haskell; Ulf Ekelund Journal: Lancet Date: 2012-07-21 Impact factor: 79.321
Authors: Francesco Landi; Emanuele Marzetti; Anna M Martone; Roberto Bernabei; Graziano Onder Journal: Curr Opin Clin Nutr Metab Care Date: 2014-01 Impact factor: 4.294
Authors: John M Jakicic; Wendy C King; Bethany Barone Gibbs; Renee J Rogers; Amy D Rickman; Kelliann K Davis; Abdus Wahed; Steven H Belle Journal: J Phys Act Health Date: 2015-01-19
Authors: Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni Journal: Age Ageing Date: 2010-04-13 Impact factor: 10.668
Authors: Shahram Oveisgharan; Lei Yu; Robert J Dawe; David A Bennett; Aron S Buchman Journal: J Gerontol A Biol Sci Med Sci Date: 2020-03-09 Impact factor: 6.053
Authors: David M Buchner; Eileen Rillamas-Sun; Chongzhi Di; Michael J LaMonte; Stephen W Marshall; Julie Hunt; Yuzheng Zhang; Dori E Rosenberg; I-Min Lee; Kelly R Evenson; Amy H Herring; Cora E Lewis; Marcia L Stefanick; Andrea Z LaCroix Journal: J Am Geriatr Soc Date: 2017-07-29 Impact factor: 5.562
Authors: Davis A Englund; Kevin A Murach; Cory M Dungan; Vandré C Figueiredo; Ivan J Vechetti; Esther E Dupont-Versteegden; John J McCarthy; Charlotte A Peterson Journal: Am J Physiol Cell Physiol Date: 2020-04-22 Impact factor: 4.249
Authors: Samuel T H Chew; Geetha Kayambu; Charles Chin Han Lew; Tze Pin Ng; Fangyi Ong; Jonathan Tan; Ngiap Chuan Tan; Shuen-Loong Tham Journal: BMC Geriatr Date: 2021-05-17 Impact factor: 3.921